In T2DM patients with low ejection-fraction HF and HbA1cabove target despite dual therapy with METFORMIN and an SGLT2 inhibitor, the institution of TRIPLE THERAPY by adding (alternatively to GLP1-RA) an AD or insulin-based therapy is recommended to improve blood glucose control. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.